CTRI/2010/091/003010已完成4 期
An open label, non-comparative, multicentre, phase IV study to evaluate the safety, tolerability and efficacy of TINEFCON in patients with plaque psoriasis
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 299
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects of at least 18 years of age with clinical diagnosis of plaque psoriasis
- •2.Subject who understand and willing to sign informed consent document before start of any study specific assessment
排除标准
- •1.Pregnant and lactating females
- •2.Subject with active infection, acute or chronic due to bacteria, viruses, fungi or parasites (most notably tuberculosis, and chronic hepatitis B)
- •3.Subject with heart failure (New York Heart Association class III or IV)
- •4.Subject with demyelinating disease
- •5.Subject with solid cancer or hematologic malignancy diagnosed within last 5 years with a potential for progression
- •6.Women of childbearing potential [defined as a sexually mature woman who has not undergone hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e. who has had menses any time in the preceding 24 consecutive months)] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) after signing an informed consent document (ICD), during the duration of study participation and for at least 4 week after withdrawal from the study, unless they are surgically sterilized
- •7.Subject with situations associated with a high risk of infection such as latent untreated tuberculosis, joint prosthesis infection within last 12 months, indwelling urinary catheter, uncontrolled diabetes, chronic obstructive pulmonary disease, skin ulcer
- •8.Subject with known premalignant lesions (such as polyps in the colon or urinary bladder, cervical dysplasia and myelodysplasia)
- •9.Subject known to be seropositive and/or clinically suspected to have the human immunodeficiency virus infection
- •10.Subject with any condition that might make it difficult for the subject to participate in the study, at the discretion of the Investigator.
研究者
相似试验
进行中（未招募）
1 期
An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant major depressive disorder.The medical condition being treated by this protocol is single or recurrent major depressive disorder (MDD), not responding to at least one adequate SSRI treatment, however, the patients being treated should be naïve to any atypical antipsychotic.MedDRA version: 8.0Classification code 10025453EUCTR2005-001737-15-BEV AstraZeneca SA40
招募中
4 期
Phase 4 study of Panitumumab in advanced colorectal cancerCTRI/2014/08/004843Dr Reddys Laboratories Limited
尚未招募
4 期
A non-comparative Phase-IV clinical trial to evaluate safety and efficacy of FDC of Fluoxetine HCl 20mg plus Alprazolam 0.25mg tablet in patients diagnosed with depressive disorderCTRI/2020/05/025240Salute Bestochem Pvt Ltd
未知
2 期
A multi-center, open label, non-randomized, phase II study to assess the activity and safety of cetuximab plus irinotecan in subjects with EGFR-detectable metastatic colorectal carcinomaColorectal carcinomaJPRN-jRCT2080220192Bristol-Myers K.K.38
已完成
2 期
Clinical study on Ampop tablet in healthy participants.CTRI/2023/03/050976Transformative Learning Solutions Private Limited